Next, we used the curve shift method to study the combination of the MEK inhibitor trametinib and the BRAF inhibitor dabrafenib, which has shown synergistic activity in BRAF-mutant melanoma cell lines [28], and in melanoma patients [40]. Here, BRAF is linked to melanoma.